NK Cell ImmunoGraft® Platform

Harnessing NK cell-mediated cytotoxicity has gained interest as a therapeutic strategy for anti-cancer therapeutics. Consequently there has been a drive for improved preclinical models supporting the translation of NK Cell-mediated therapies to the clinic.

Champions Oncology offers a unique NK cell ImmunoGraft® platform in which human NK cells which have been purified from peripheral blood mononuclear cells (PBMC) or differentiated in vivo from CD34+ umbilical cord blood hematopoetic stem cells are engrafted into immunodeficient mice transgenically expressing human cytokines such as IL-2 or IL-15. These animals are then co-engrafted with a PDX or CDX model and evaluated with therapeutic drugs and standards of care for direct NK-cell mediated or antibody-dependent cellular cytotoxicity (ADCC) via efficacy and pharmacodynamic readouts.

NK Cell ImmunoGraft

Champions Oncology’s NK Cell ImmunoGraft® Platform